relapsed/refractory Large B-Cell Lymphoma research hub

Double-T - Improving outcomes in high-risk 2nd line relapsed/refractory Large B-Cell Lymphoma patients eligible for CAR-T-cell therapy with a Glofitamab-based induction and consolidation concept

This study looks at new ways to treat a type of cancer called Large B-Cell Lymphoma that has come back or not responded to usual treatments. It uses a combination of medicines, including CAR-T cell therapy, to see if it can help more patients achieve complete remission.